Therapeutic advancement of chronic lymphocytic leukemia.
about
Novel agents for chronic lymphocytic leukemiaSTAT inhibitors for cancer therapy.Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphomaDetection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.Targeting p53 by small molecules in hematological malignancies.Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.Ellagic acid, a polyphenolic compound, selectively induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL patients by directly targeting mitochondriaThe role of peptide and DNA vaccines in myeloid leukemia immunotherapyThe role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathwayIbrutinib for B cell malignancies.Role of high expression of IL-9 in prognosis of CLL.Ibrutinib and novel BTK inhibitors in clinical development.Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt/β-catenin pathway.Correlation of Cadmium and Magnesium in the Blood and Serum Samples of Smokers and Non-Smokers Chronic Leukemia Patients.Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock.
P2860
Q21198858-AF5AE2DB-3FD9-4ACB-8924-DA5B61D6A6CDQ33644206-70D27D21-46D7-4F93-A3E1-018D2FF90B06Q34255861-ECB7FBA8-4305-4042-A782-4948ED921C8EQ34461989-48920494-109B-41EC-91F8-06F59005B93BQ34636996-BF69015F-7FFE-4371-B43A-D3000A12A355Q35184110-7813018F-26B5-418B-A25E-82F289BF090DQ36106326-11AFBD73-838E-4E9A-ACD9-50677FBCCA3AQ36608571-FF9ED300-B786-45BB-B7FD-171823D2B7B3Q37365776-3DD1B9CE-0A82-484D-8098-48EF4F98F925Q37541654-32AB2794-E1C5-4B81-8298-7577F1570AC0Q37555418-DF562F43-D229-414B-9954-431023348A8CQ37587401-F50E539F-5983-4B3D-A737-73DF8A592B50Q38130010-BBD56A2C-4484-4584-855F-B5382904EADDQ38260357-7A5510C6-4FA0-4D0E-A9F6-BEB7CA71F2F6Q38921580-B2D64D33-154F-4A65-A376-FA237497C2B7Q39502120-6F6DE6BE-5AA1-4092-86FB-28FD87A4B8CBQ41947180-8207D32E-9EB6-49F5-A699-7022295E6B14Q53062630-DF89C2A9-D476-41E2-B2D8-BD86CF82D7D5
P2860
Therapeutic advancement of chronic lymphocytic leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Therapeutic advancement of chronic lymphocytic leukemia.
@ast
Therapeutic advancement of chronic lymphocytic leukemia.
@en
type
label
Therapeutic advancement of chronic lymphocytic leukemia.
@ast
Therapeutic advancement of chronic lymphocytic leukemia.
@en
prefLabel
Therapeutic advancement of chronic lymphocytic leukemia.
@ast
Therapeutic advancement of chronic lymphocytic leukemia.
@en
P2860
P921
P356
P1476
Therapeutic advancement of chronic lymphocytic leukemia.
@en
P2093
P2860
P2888
P356
10.1186/1756-8722-5-55
P5008
P577
2012-09-16T00:00:00Z
P5875
P6179
1040316354